SkyView Investment Advisors LLC Has $828,000 Stake in Liquidia Co. (NASDAQ:LQDA)

SkyView Investment Advisors LLC lowered its position in Liquidia Co. (NASDAQ:LQDA) by 26.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 68,999 shares of the company’s stock after selling 24,254 shares during the quarter. SkyView Investment Advisors LLC owned approximately 0.09% of Liquidia worth $828,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quest Partners LLC acquired a new stake in Liquidia in the 2nd quarter valued at about $27,000. Hilltop National Bank bought a new position in shares of Liquidia during the 2nd quarter worth approximately $33,000. Deuterium Capital Management LLC acquired a new position in shares of Liquidia during the 2nd quarter worth approximately $120,000. DMC Group LLC bought a new stake in Liquidia in the 2nd quarter valued at $122,000. Finally, Whitcomb & Hess Inc. acquired a new stake in Liquidia during the 2nd quarter valued at $126,000. Institutional investors own 64.54% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Michael Kaseta sold 3,906 shares of the business’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the transaction, the chief financial officer now directly owns 312,389 shares in the company, valued at approximately $3,914,234.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Liquidia news, Director Caligan Partners Lp bought 150,000 shares of Liquidia stock in a transaction on Friday, August 30th. The shares were purchased at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the acquisition, the director now owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Michael Kaseta sold 3,906 shares of the business’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the transaction, the chief financial officer now directly owns 312,389 shares of the company’s stock, valued at approximately $3,914,234.17. The disclosure for this sale can be found here. Insiders have sold 21,422 shares of company stock worth $256,998 over the last ninety days. Corporate insiders own 31.60% of the company’s stock.

Liquidia Trading Down 1.3 %

Shares of LQDA stock opened at $10.01 on Friday. The stock has a market cap of $764.90 million, a P/E ratio of -6.42 and a beta of 0.22. Liquidia Co. has a 1 year low of $5.71 and a 1 year high of $16.99. The stock has a 50 day simple moving average of $10.58 and a 200 day simple moving average of $12.42.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The company had revenue of $3.66 million for the quarter, compared to the consensus estimate of $7.92 million. Analysts forecast that Liquidia Co. will post -1.71 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on LQDA shares. HC Wainwright dropped their price objective on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. BTIG Research lowered their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Bank of America reduced their price objective on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Finally, Oppenheimer assumed coverage on Liquidia in a research note on Tuesday, June 25th. They issued a “market perform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.14.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).